At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
DXCM DexCom
Market Closed 12-20 16:00:00 EST
80.04
+4.22
+5.57%
盘后80.04
+0.000.00%
19:56 EST
High81.51
Low75.47
Vol11.58M
Open75.47
D1 Closing75.82
Amplitude7.97%
Mkt Cap31.26B
Tradable Cap31.06B
Total Shares390.60M
T/O922.94M
T/O Rate2.98%
Tradable Shares388.00M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
1 Reason to Sell DexCom Stock, and 1 Reason to Buy
Alberta Government Lifts Age Restrictions on Continuous Glucose Monitors (Cgm) and Eligible Albertans With Type 1 or Type 2 Diabetes Can NOW Access Dexcom G7 Cgm
Alberta Government Lifts Age Restrictions on Continuous Glucose Monitors (CGM) and Eligible Albertans With Type 1 or Type 2 Diabetes Can Now Access Dexcom G7 CGM
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.